Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: Therapeutic implications

Blood

Volumn 113, Issue 21, 2009, Pages 5228-5236

  Hideshima, Teru ^a   Chauhan, Dharminder ^a   Kiziltepe, Tanyel ^a   Ikeda, Hiroshi ^a   Okawa, Yutaka ^a   Podar, Klaus ^a   Raje, Noopur ^a   Protopopov, Alexei ^a   Munshi, Nikhil C ^a   Richardson, Paul G ^a   Carrasco, Ruben D ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; AURORA A KINASE; BETA CATENIN; I KAPPA B KINASE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE INHIBITOR; MLN 120B; TANESPIMYCIN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN SUBUNIT;

ARTICLE; BONE MARROW; CELL ADHESION; CELL GROWTH; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA CELL; SURVIVAL; TREATMENT PLANNING; BONE MARROW CELL; CELL PROLIFERATION; CYTOLOGY; DRUG ANTAGONISM; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BONE MARROW CELLS; CELL ADHESION; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; I-KAPPA B KINASE; MULTIPLE MYELOMA; NF-KAPPA B; PROTEIN SUBUNITS; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 67149089043     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-161505     Document Type: Article

References (49)

1. kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 2000;19:4319-4327.
2. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585-598.
3. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-683. (Pubitemid 26130197)
4. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-16647. (Pubitemid 34967682)
5. Hideshima T, Neri P, Tassone P, et al. MLN120B, a novel IKKβ inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006;12:5887-5894. (Pubitemid 44629622)
6. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12:115-130. (Pubitemid 47199123)
7. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell. 2007;12:131-144. (Pubitemid 47208626)
8. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell. 1997;91:243-252. (Pubitemid 27456391)
9. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749-759. (Pubitemid 41400849)
10. Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006;66:6675-6682. (Pubitemid 44085624)
11. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107:4053-4062. (Pubitemid 43726814)
12. Wen D, Nong Y, Morgan JG, et al. A selective small molecule IκB Kinase beta inhibitor blocks nuclear factor κB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. J Pharmacol Exp Ther. 2006;317:989-1001. (Pubitemid 43764101)
13. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530-1534. (Pubitemid 36182530)
14. Carrasco DR, Sukhdeo K, Protopopov M, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 2007;11:349-360. (Pubitemid 46518314)
15. Hideshima T, Catley L, Raje N, et al. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007;138:783-791. (Pubitemid 47313207)
16. Jost PJ, Ruland J. Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109:2700-2707. (Pubitemid 46482061)
17. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol. 2007;8:49-62. (Pubitemid 46012014)
18. Lamberti C, Lin KM, Yamamoto Y, et al. Regulation of β-catenin function by the IkappaB kinases. J Biol Chem. 2001;276:42276-44286. (Pubitemid 37371138)
19. Albanese C, Wu K, D'Amico M, et al. IKKα regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Mol Biol Cell. 2003;14:585-599. (Pubitemid 36237018)
20. Derksen PW, Tjin E, Meijer HP, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A. 2004;101:6122-6127. (Pubitemid 38520538)
21. Qiang YW, Endo Y, Rubin JS, Rudikoff S. Wnt signaling in B-cell neoplasia. Oncogene. 2003;22:1536-1545.
22. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483-2494. (Pubitemid 38010074)
23. Prajapati S, Tu Z, Yamamoto Y, Gaynor RB. IKKα regulates the mitotic phase of the cell cycle by modulating Aurora A phosphorylation. Cell Cycle. 2006;5:2371-2380. (Pubitemid 44785847)
24. Sukhdeo K, Mani M, Zhang Y, et al. Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A. 2007;104:7516-7521. (Pubitemid 47185938)
25. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006;107:1092-1100. (Pubitemid 43156310)
26. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol. 2002;3:221-227.
27. Kim HJ, Hawke N, Baldwin AS. NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ. 2006;13:738-747.
28. Van Waes C. Nuclear factor-κB in development, prevention, and therapy of cancer. Clin Cancer Res. 2007;13:1076-1082. (Pubitemid 46424045)
29. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 1999;19:2690-2698. (Pubitemid 29144513)
30. Badrichani AZ, Stroka DM, Bilbao G, Curiel DT, Bach FH, Ferran C. Bcl-2 and Bcl-XL serve an anti-inflammatory function in endothelial cells through inhibition of NF-κB. J Clin Invest. 1999;103:543-553. (Pubitemid 29094055)
31. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG. NF-κB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 2001;12:73-90. (Pubitemid 32294588)
32. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076. (Pubitemid 32691956)
33. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002;99:14374-14379. (Pubitemid 35257679)
34. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617. (Pubitemid 36741588)
35. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J Biol Chem. 2001;276:22382-22387. (Pubitemid 37410912)
36. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525-4530. (Pubitemid 34627223)
37. Catley L, Weisberg E, Tai YT, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003;102:2615-2622. (Pubitemid 37193603)
38. Hayashi T, Hideshima T, Nguyen AN, et al. TGF-β receptor I kinase inhibitor downregulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res. 2004;10:7540-7546. (Pubitemid 39557515)
39. Hideshima T, Chauhan D, Hayashi T, et al. Antitumor activity of lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003;63:8428-8436. (Pubitemid 37549499)
40. Ito K, Nakazato T, Xian MJ, et al. 1′-acetoxychavicol acetate is a novel nuclear factor κB inhibitor with significant activity against multiple myeloma in vitro and in vivo. Cancer Res. 2005;65:4417-4424. (Pubitemid 40775681)
41. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell. 2005;8:407-419. (Pubitemid 41579835)
42. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21:5673-5683. (Pubitemid 35333000)
43. Yamamoto Y, Yin MJ, Gaynor RB. IκB kinase α (IKKα) regulation of IKKβ kinase activity. Mol Cell Biol. 2000;20:3655-3666.
44. Yamamoto Y, Gaynor RB. IκB kinases: key regulators of the NF-κB pathway. Trends Biochem Sci. 2004;29:72-79. (Pubitemid 38186577)
45. Qiang YW, Walsh K, Yao L, et al. Wnts induce migration and invasion of myeloma plasma cells. Blood. 2005;106:1786-1793. (Pubitemid 41208595)
46. Shi Y, Reiman T, Li W, et al. Targeting aurora kinases as therapy in multiple myeloma. Blood. 2007;109:3915-3921. (Pubitemid 46641744)
47. Broemer M, Krappmann D, Scheidereit C. Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation. Oncogene. 2004;23:5378-5386. (Pubitemid 39005813)
48. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood. 1996;87:1104-1112. (Pubitemid 26043538)
49. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells. Oncogene. 2003;22:2417-2421. (Pubitemid 36560725)